TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27729164

Group type: EXPERIMENTAL
Intervention: Preemptive intra-articular 20 mL of bupivacaine 0.5% injection
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Preemptive periacetabular 20 mL of bupivacaine 0.5% injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Total analgesic consumption
Number of subjects: 42
Study: 26924418

Group type: EXPERIMENTAL
Intervention: Epi-No(®) device
Number of subjects: 660
Study: 24909413

Group type: EXPERIMENTAL
Intervention: Deep Sedation (DS) using propofol
Number of subjects: 21

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 21
Study: 22304690

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sham TENS (placebo)
Number of subjects: 165
Study: 20498251

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 23
Study: 18727076

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 16
Study: 15911188

Group type: EXPERIMENTAL
Intervention: Ethnic specific diabetes education
Number of subjects: 45
Study: 12870691

Group type: EXPERIMENTAL
Intervention: Standard regimen of antituberculosis chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen containing isoniazid, rifampicin, and ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 0
Study: 10229720

Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 206

Group type: COMPARATOR
Intervention: General Ward (GW)
Number of subjects: 206
Study: 9175240

Group type: EXPERIMENTAL
Intervention: Pectin supplement (15 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (15 g/day)
Number of subjects: 20
Study: 1531821

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 4002804

Group type: COMPARATOR
Intervention: Indapamide (2.5 mg per day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Muzolimine (20 mg per day)
Number of subjects: 58
Study: 31524143

Group type: EXPERIMENTAL
Intervention: 9-long non-coding RNA signature
Number of subjects: 493
Study: 29609926

Group type: EXPERIMENTAL
Intervention: Low Dose Group (LDG): Two 90-min yoga classes plus three 30-min homework sessions weekly for 12 weeks.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High Dose Group (HDG): Three 90-min yoga classes plus four 30-min homework sessions weekly for 12 weeks.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 32
Study: 27993164

Group type: EXPERIMENTAL
Intervention: Professional development (PD) intervention for early childhood educators
Number of subjects: 90

Group type: COMPARATOR
Intervention: Typical classroom practice (Control)
Number of subjects: 90
Study: 25831644

Group type: EXPERIMENTAL
Intervention: Modified Limberg's flap closure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Excision and primary closure
Number of subjects: 60
Study: 22374639

Group type: EXPERIMENTAL
Intervention: Aerobic exercise before resistance exercise (AR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resistance exercise before aerobic exercise (RA)
Number of subjects: 12
Study: 19028741

Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.05% isotonic Indocyanine Green (ICG)‐assisted ILM peeling
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.15% Trypan Blue (TB)‐assisted ILM peeling
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vitrectomy alone without retinal surface manipulation
Number of subjects: 78
Study: 18158672

Group type: EXPERIMENTAL
Intervention: IVIMEDS' CVS module
Number of subjects: 50

Group type: COMPARATOR
Intervention: Existing CVS resources
Number of subjects: 50
Study: 15101859

Group type: EXPERIMENTAL
Intervention: Morphine (50 micro g kg(‐1) loading dose, followed by intravenous morphine-PCA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Rescue medication (1 mg of morphine)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nausea incidence
Number of subjects: 64
Study: 11194215

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ordinary sodium diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sodium sensitivity index
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Blood pressure readings <130/85 mmHg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of urinary albumin
Number of subjects: 32
Study: 8126472

Group type: COMPARATOR
Intervention: Ivermectin 0, 6, 12, and 24 micrograms/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin 0, 15, 30, 60, and 120 micrograms/kg
Number of subjects: 0
Study: 2882060

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29548304

Group type: EXPERIMENTAL
Intervention: Coordinated medication management model (CoMM) involving practical nurses and clinical pharmacists
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Interprofessional triage meeting
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Community pharmacists conducting medication reviews
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Implementation and follow-up of medication changes
Number of subjects: 191
Study: 28473063

Group type: EXPERIMENTAL
Intervention: High protein (HP) diet (1.5 g•kg‐1•d‐1 protein)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal protein diet (0.8 g•kg‐1•d‐1 protein)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both diets (HP and normal protein)
Number of subjects: 32
Study: 26287955

Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 87
Study: 23340711

Group type: EXPERIMENTAL
Intervention: Web-based psychosocial treatment
Number of subjects: 506
Study: 18272264

Group type: EXPERIMENTAL
Intervention: Adjuvant Systems containing MPL/QS21 (AS02B, AS02V, AS01B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CpG oligonucleotide
Number of subjects: 100
Study: 16481707

Group type: EXPERIMENTAL
Intervention: 1% lindane cream
Number of subjects: 99

Group type: COMPARATOR
Intervention: 5% permethrin cream
Number of subjects: 99
Study: 12582352

Group type: EXPERIMENTAL
Intervention: Single-dose clindamycin (600 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 24-hour clindamycin prophylaxis (600 mg total)
Number of subjects: 70
Study: 10701819

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 162

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 162
Study: 9337609

Group type: EXPERIMENTAL
Intervention: Typical daily dose of caffeine (400-1000 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mg of caffeine in excess of daily consumption
Number of subjects: 24
Study: 7903212

Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol (T) once daily
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 3119650

Group type: EXPERIMENTAL
Intervention: GnRH (100 micrograms) injected iv on the fifth day of consecutive cycles after an ovulatory cycle
Number of subjects: 10

Group type: COMPARATOR
Intervention: GnRH (100 micrograms) injected iv on the fifth day of consecutive cycles after an anovulatory cycle
Number of subjects: 10
Study: 29860937

Group type: COMPARATOR
Intervention: Sunitinib alone (50 mg daily in cycles of 28 days on and 14 days off)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Nephrectomy followed by sunitinib (50 mg daily in cycles of 28 days on and 14 days off)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Sunitinib alone
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Nephrectomy followed by sunitinib
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Sunitinib alone and Nephrectomy followed by sunitinib
Number of subjects: 450
Study: 26444773

Group type: EXPERIMENTAL
Intervention: Memory group intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 219
Study: 26112885

Group type: EXPERIMENTAL
Intervention: ICD implantation with defibrillation (DF) testing, n = 540
Number of subjects: 1077

Group type: COMPARATOR
Intervention: ICD implantation without defibrillation (DF) testing, n = 537
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: ICD implantation with DF testing, n = 540
Number of subjects: 1077

Group type: COMPARATOR
Intervention: ICD implantation without DF testing, n = 537
Number of subjects: 1077
Study: 21953134

Group type: EXPERIMENTAL
Intervention: Standardized cognitive training (COGPACK)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine occupational therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Psychoeducational group program (8 sessions within 4 weeks)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Follow-up after 9 months
Number of subjects: 116
Study: 21356050

Group type: EXPERIMENTAL
Intervention: Conservative management (immobilisation in a sling at the side in internal rotation for 6 weeks or until clinical or radiological union)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (surgical treatment using the Acumed clavicle fixation system)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 300

Group type: COMPARATOR
Intervention: Open reduction and internal fixation
Number of subjects: 300
Study: 19175551

Group type: EXPERIMENTAL
Intervention: Applied muscle tension conditions (various muscle groups)
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Donation as usual (control group)
Number of subjects: 1059
Study: 18235928

Group type: EXPERIMENTAL
Intervention: Fundoplication with division of short gastric vessels (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fundoplication without division of short gastric vessels (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 90
Study: 14769685

Group type: EXPERIMENTAL
Intervention: Slow-release paclitaxel-eluting stents (SR)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Moderate-release paclitaxel-eluting stents (MR)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 427
Study: 11794698

Group type: EXPERIMENTAL
Intervention: Clustered dosage (5 consecutive daily infusions at 5-week intervals)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nonclustered dosage (1 infusion weekly)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 20
Study: 9426718

Group type: EXPERIMENTAL
Intervention: BTA TRAK assay
Number of subjects: 216

Group type: COMPARATOR
Intervention: Voided urine cytology (VUC)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Bard BTA test (BTA)
Number of subjects: 216
Study: 8506782

Group type: EXPERIMENTAL
Intervention: Alcohol expectancy in women
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alcohol consumption in both men and women
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control for beliefs
Number of subjects: 64

Group type: COMPARATOR
Intervention: Alcohol expectancy in men
Number of subjects: 64
Study: 3090603

Group type: EXPERIMENTAL
Intervention: Skills intervention group
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Discussion intervention group
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1281
Study: 29544905

Group type: EXPERIMENTAL
Intervention: CellScope Oto® smartphone device
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional otoscope
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control exam by treating physician
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Parental preference
Number of subjects: 94
Study: 27272076

Group type: EXPERIMENTAL
Intervention: Bimatoprost plus mometasone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bimatoprost monotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mometasone plus placebo
Number of subjects: 32
Study: 24401214

Group type: EXPERIMENTAL
Intervention: Intensive rosuvastatin therapy (achieve 30% lower LDL-C levels than standard)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard rosuvastatin therapy (achieve LDL-C levels recommended by Japanese guidelines)
Number of subjects: 60
Study: 23521655

Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg.kg(‐1)) and propofol infusion (1.0 μg.ml(‐1) effect-site concentration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flumazenil administration
Number of subjects: 20
Study: 21177169

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg) every night for 3 months in HLT and NLT groups
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo for 3 months in HLC and NLC groups
Number of subjects: 85
Study: 17996239

Group type: EXPERIMENTAL
Intervention: Incredible Years Parenting Program (12-week duration)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 16008604

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with cyclosporine microemulsion
Number of subjects: 0
Study: 14576764

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (exact dosage not specified)
Number of subjects: 168
Study: 10553392

Group type: EXPERIMENTAL
Intervention: 22-mg, 24-hour nicotine patch therapy (active patch)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 958

Group type: EXPERIMENTAL
Intervention: 22-mg, 24-hour nicotine patch therapy (open label-pay)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Placebo (in comparison with open label-pay)
Number of subjects: 958
Study: 8647491

Group type: EXPERIMENTAL
Intervention: Mononuclear cells from umbilical blood
Number of subjects: 31
Study: 2066891

Group type: EXPERIMENTAL
Intervention: Material A
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Material B
Number of subjects: 14
Study: 6683539

Group type: EXPERIMENTAL
Intervention: Capsule (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tablet (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral solution (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tablets (150 mg, 300 mg, 600 mg)
Number of subjects: 12
Study: 31771448

Group type: EXPERIMENTAL
Intervention: Structured pre-simulation preparation and briefing (35 minutes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional preparation and briefing
Number of subjects: 80
Study: 30170568

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - single-fraction 24 Gy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT) - 30 Gy/10 fractions
Number of subjects: 55
Study: 26911262

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (up to three nutritional sessions conducted by a bilingual dietitian)
Number of subjects: 18
Study: 24246768

Group type: EXPERIMENTAL
Intervention: Probiotics (1 × 10(8) colony‐forming units, 3 times daily; n = 86)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No test article (control; n = 74)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 160

Group type: COMPARATOR
Intervention: No test article (control)
Number of subjects: 160
Study: 22561055

Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB) 1 mg twice daily for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nebulized budesonide (NEB) 1 mg twice daily for 8 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB)
Number of subjects: 25
Study: 18632181

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (33.3 mg/m² on days 1, 8, 15 q 4 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Weekly docetaxel (30 mg/m² on days 1, 8, 15) plus gemcitabine (800 mg/m² on days 1, 8 q 4 weeks) or plus vinorelbine (20 mg/m² on days 1, 8 q 4 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Weekly docetaxel (as in arm B) plus capecitabine (625 mg/m² twice daily on days 5-18 q 4 weeks)
Number of subjects: 84
Study: 16907846

Group type: EXPERIMENTAL
Intervention: HBIg 400 IU intramuscularly once a month at the third, second and first month before delivery
Number of subjects: 250

Group type: COMPARATOR
Intervention: No antepartum treatment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: HBIg 400 IU intramuscularly
Number of subjects: 250
Study: 14691614

Group type: EXPERIMENTAL
Intervention: Carbamazepine (600 mg daily except 200 mg daily for the first 2 days)
Number of subjects: 12
Study: 11297908

Group type: EXPERIMENTAL
Intervention: Scopolamine nasal spray (0.2%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9550476

Group type: EXPERIMENTAL
Intervention: Iloprost (50 microg orally twice daily)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 7909209

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study: 3076492

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (10 mg b.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31344528

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 1037
Study: 28733813

Group type: EXPERIMENTAL
Intervention: Active cannabis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active tobacco
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo tobacco
Number of subjects: 24
Study: 25626575

Group type: EXPERIMENTAL
Intervention: Berlin Heart EXCOR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infant Jarvik 2000
Number of subjects: 0
Study: 23497020

Group type: EXPERIMENTAL
Intervention: Fermented turmeric powder (FTP) 3.0 g per day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo 3.0 g per day for 12 weeks
Number of subjects: 60
Study: 21476202

Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA) at Hegu (LI4) and Sanyinjiao (SP6) points
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 38
Study: 17875549

Group type: EXPERIMENTAL
Intervention: 3 g of omega-3-polyunsaturated fatty acids
Number of subjects: 60
Study: 14735648

Group type: EXPERIMENTAL
Intervention: 2 hours of bed rest (experimental group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 4 hours of bed rest (control group)
Number of subjects: 68
Study: 12409561

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study: 9824785

Group type: EXPERIMENTAL
Intervention: K4MgCit2 (49 mEq K, 25 mEq Mg, and 74 mEq citrate/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: K3MgHCit2 (49 mEq K, 33 mEq Mg, and 98 mEq citrate/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: K5MgCit2Cl (49 mEq K, 20 mEq Mg, 10 mEq Cl and 59 mEq citrate/day)
Number of subjects: 62
Study: 7661060

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (53% of patients treated with a thrombolytic agent in 1992)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (no thrombolytic therapy in 1966 and 1981-1983)
Number of subjects: 0
Study: 2757244

Group type: EXPERIMENTAL
Intervention: Isoproterenol 5 micrograms iv
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (NS group; n = 10)
Number of subjects: 20
Study: 6815

Group type: EXPERIMENTAL
Intervention: 30 ml of ipecac orally
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.1 mg/kg apomorphine subcutaneously
Number of subjects: 28
Study: 31028971

Group type: EXPERIMENTAL
Intervention: Asian wet cupping technique
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Traditional Hijamah technique
Number of subjects: 70
Study: 28377403

Group type: EXPERIMENTAL
Intervention: Rapid flow expulsion maneuver
Number of subjects: 16
Study: 25632066

Group type: EXPERIMENTAL
Intervention: C‐GEMOX (500 mg/m² cetuximab plus GEMOX: 800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: GEMOX (800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Number of subjects: 122
Study: 23442047

Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo-cisplatin
Number of subjects: 111
Study: 21613792

Group type: EXPERIMENTAL
Intervention: Candesartan (n = 21)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment without inhibitors of the renin-angiotensin-aldosterone system (n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls (n = 20)
Number of subjects: 42
Study: 19661125

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 22

Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 22
Study: 16953530

Group type: EXPERIMENTAL
Intervention: Combination therapy (morphine 5 mg at time zero and 5 mg at 20 minutes, ketorolac 15 mg at time zero and 15 mg at 20 minutes)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Morphine alone (5 mg at time zero and 5 mg at 20 minutes)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ketorolac alone (15 mg at time zero and 15 mg at 20 minutes)
Number of subjects: 130
Study: 14764773

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate daily for 2 years
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol plus 1 mg norethisterone acetate daily for 2 years (HRT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of alendronate and HRT for 2 years
Number of subjects: 90
Study: 11590393

Group type: EXPERIMENTAL
Intervention: Wheat ω-5 gliadin IgE antibody testing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral wheat challenge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Skin prick testing with ω-5 gliadin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (children with no evidence of food allergies)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wheat ω-5 gliadin ELISA
Number of subjects: 40
Study: 9220180

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 21